Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics.

Lallo A, Gulati S, Schenk MW, Khandelwal G, Berglund UW, Pateras IS, Chester CPE, Pham TM, Kalderen C, Frese KK, Gorgoulis VG, Miller C, Blackhall F, Helleday T, Dive C.

Br J Pharmacol. 2019 Feb;176(3):436-450. doi: 10.1111/bph.14542. Epub 2018 Dec 13.

PMID:
30427531
2.

Will liquid biopsies improve outcomes for patients with small-cell lung cancer?

Blackhall F, Frese KK, Simpson K, Kilgour E, Brady G, Dive C.

Lancet Oncol. 2018 Sep;19(9):e470-e481. doi: 10.1016/S1470-2045(18)30455-8. Review.

PMID:
30191851
3.

Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin.

Torres-Ayuso P, Sahoo S, Ashton G, An E, Simms N, Galvin M, Leong HS, Frese KK, Simpson K, Cook N, Hughes A, Miller CJ, Marais R, Dive C, Krebs MG, Brognard J.

NPJ Genom Med. 2018 Jun 20;3:15. doi: 10.1038/s41525-018-0055-6. eCollection 2018.

4.

The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.

Lallo A, Frese KK, Morrow CJ, Sloane R, Gulati S, Schenk MW, Trapani F, Simms N, Galvin M, Brown S, Hodgkinson CL, Priest L, Hughes A, Lai Z, Cadogan E, Khandelwal G, Simpson KL, Miller C, Blackhall F, O'Connor MJ, Dive C.

Clin Cancer Res. 2018 Oct 15;24(20):5153-5164. doi: 10.1158/1078-0432.CCR-17-2805. Epub 2018 Jun 25.

PMID:
29941481
5.

Targeting DNA damage in SCLC.

Foy V, Schenk MW, Baker K, Gomes F, Lallo A, Frese KK, Forster M, Dive C, Blackhall F.

Lung Cancer. 2017 Dec;114:12-22. doi: 10.1016/j.lungcan.2017.10.006. Epub 2017 Oct 16. Review.

PMID:
29173760
6.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ.

Cancer Res. 2017 Nov 1;77(21):e62-e66. doi: 10.1158/0008-5472.CAN-17-0582.

7.

Circulating tumor cells and CDX models as a tool for preclinical drug development.

Lallo A, Schenk MW, Frese KK, Blackhall F, Dive C.

Transl Lung Cancer Res. 2017 Aug;6(4):397-408. doi: 10.21037/tlcr.2017.08.01. Review.

8.

Next-Generation Sequencing Analysis and Algorithms for PDX and CDX Models.

Khandelwal G, Girotti MR, Smowton C, Taylor S, Wirth C, Dynowski M, Frese KK, Brady G, Dive C, Marais R, Miller C.

Mol Cancer Res. 2017 Aug;15(8):1012-1016. doi: 10.1158/1541-7786.MCR-16-0431. Epub 2017 Apr 25.

9.

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.

Hessmann E, Patzak MS, Klein L, Chen N, Kari V, Ramu I, Bapiro TE, Frese KK, Gopinathan A, Richards FM, Jodrell DI, Verbeke C, Li X, Heuchel R, Löhr JM, Johnsen SA, Gress TM, Ellenrieder V, Neesse A.

Gut. 2018 Mar;67(3):497-507. doi: 10.1136/gutjnl-2016-311954. Epub 2017 Jan 10.

10.

Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.

Morrow CJ, Trapani F, Metcalf RL, Bertolini G, Hodgkinson CL, Khandelwal G, Kelly P, Galvin M, Carter L, Simpson KL, Williamson S, Wirth C, Simms N, Frankliln L, Frese KK, Rothwell DG, Nonaka D, Miller CJ, Brady G, Blackhall FH, Dive C.

Ann Oncol. 2016 Jun;27(6):1155-60. doi: 10.1093/annonc/mdw122. Epub 2016 Mar 24.

11.

PLAC8 Localizes to the Inner Plasma Membrane of Pancreatic Cancer Cells and Regulates Cell Growth and Disease Progression through Critical Cell-Cycle Regulatory Pathways.

Kaistha BP, Lorenz H, Schmidt H, Sipos B, Pawlak M, Gierke B, Kreider R, Lankat-Buttgereit B, Sauer M, Fiedler L, Krattenmacher A, Geisel B, Kraus JM, Frese KK, Kelkenberg S, Giese NA, Kestler HA, Gress TM, Buchholz M.

Cancer Res. 2016 Jan 1;76(1):96-107. doi: 10.1158/0008-5472.CAN-15-0216. Epub 2015 Dec 15.

12.

MRI with hyperpolarised [1-13C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model.

Serrao EM, Kettunen MI, Rodrigues TB, Dzien P, Wright AJ, Gopinathan A, Gallagher FA, Lewis DY, Frese KK, Almeida J, Howat WJ, Tuveson DA, Brindle KM.

Gut. 2016 Mar;65(3):465-75. doi: 10.1136/gutjnl-2015-310114. Epub 2015 Sep 7.

13.

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.

Bapiro TE, Frese KK, Courtin A, Bramhall JL, Madhu B, Cook N, Neesse A, Griffiths JR, Tuveson DA, Jodrell DI, Richards FM.

Br J Cancer. 2014 Jul 15;111(2):318-25. doi: 10.1038/bjc.2014.288. Epub 2014 May 29.

14.

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.

Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, Tuveson DA.

Gut. 2014 Jun;63(6):974-83. doi: 10.1136/gutjnl-2013-305559. Epub 2013 Sep 25.

15.

CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.

Neesse A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, Pilarsky C, Jodrell DI, Spong SM, Tuveson DA.

Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12325-30. doi: 10.1073/pnas.1300415110. Epub 2013 Jul 8.

16.

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA.

Cancer Discov. 2012 Mar;2(3):260-269. doi: 10.1158/2159-8290.CD-11-0242. Epub 2012 Feb 28.

17.

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.

Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, Tuveson DA.

Gut. 2013 Jan;62(1):112-20. doi: 10.1136/gutjnl-2012-302529. Epub 2012 Mar 30.

18.

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.

Cook N, Frese KK, Bapiro TE, Jacobetz MA, Gopinathan A, Miller JL, Rao SS, Demuth T, Howat WJ, Jodrell DI, Tuveson DA.

J Exp Med. 2012 Mar 12;209(3):437-44. doi: 10.1084/jem.20111923. Epub 2012 Feb 20.

19.

Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice.

Gopinathan A, Denicola GM, Frese KK, Cook N, Karreth FA, Mayerle J, Lerch MM, Reinheckel T, Tuveson DA.

Gut. 2012 Jun;61(6):877-84. doi: 10.1136/gutjnl-2011-300850. Epub 2011 Dec 9.

PMID:
22157328
20.

C-Raf is required for the initiation of lung cancer by K-Ras(G12D).

Karreth FA, Frese KK, DeNicola GM, Baccarini M, Tuveson DA.

Cancer Discov. 2011 Jul;1(2):128-36. doi: 10.1158/2159-8290.CD-10-0044. Epub 2011 May 11.

21.

A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.

Bapiro TE, Richards FM, Goldgraben MA, Olive KP, Madhu B, Frese KK, Cook N, Jacobetz MA, Smith DM, Tuveson DA, Griffiths JR, Jodrell DI.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1243-53. doi: 10.1007/s00280-011-1613-0. Epub 2011 Mar 23.

22.

Stromal biology and therapy in pancreatic cancer.

Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA.

Gut. 2011 Jun;60(6):861-8. doi: 10.1136/gut.2010.226092. Epub 2010 Oct 21. Review.

PMID:
20966025
23.

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.

Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA.

Science. 2009 Jun 12;324(5933):1457-61. doi: 10.1126/science.1171362. Epub 2009 May 21.

24.

Functionally distinct monomers and trimers produced by a viral oncoprotein.

Chung SH, Weiss RS, Frese KK, Prasad BV, Javier RT.

Oncogene. 2008 Feb 28;27(10):1412-20. Epub 2007 Sep 10.

25.

Maximizing mouse cancer models.

Frese KK, Tuveson DA.

Nat Rev Cancer. 2007 Sep;7(9):645-58. Review.

PMID:
17687385
26.

A new crucial protein interaction element that targets the adenovirus E4-ORF1 oncoprotein to membrane vesicles.

Chung SH, Frese KK, Weiss RS, Prasad BV, Javier RT.

J Virol. 2007 May;81(9):4787-97. Epub 2007 Feb 21.

27.

Oncogenic function for the Dlg1 mammalian homolog of the Drosophila discs-large tumor suppressor.

Frese KK, Latorre IJ, Chung SH, Caruana G, Bernstein A, Jones SN, Donehower LA, Justice MJ, Garner CC, Javier RT.

EMBO J. 2006 Mar 22;25(6):1406-17. Epub 2006 Mar 2.

28.

Viral oncoprotein-induced mislocalization of select PDZ proteins disrupts tight junctions and causes polarity defects in epithelial cells.

Latorre IJ, Roh MH, Frese KK, Weiss RS, Margolis B, Javier RT.

J Cell Sci. 2005 Sep 15;118(Pt 18):4283-93. Epub 2005 Sep 1.

29.

Discs-Large and Strabismus are functionally linked to plasma membrane formation.

Lee OK, Frese KK, James JS, Chadda D, Chen ZH, Javier RT, Cho KO.

Nat Cell Biol. 2003 Nov;5(11):987-93. Epub 2003 Oct 19.

30.

Selective PDZ protein-dependent stimulation of phosphatidylinositol 3-kinase by the adenovirus E4-ORF1 oncoprotein.

Frese KK, Lee SS, Thomas DL, Latorre IJ, Weiss RS, Glaunsinger BA, Javier RT.

Oncogene. 2003 Feb 6;22(5):710-21.

31.

Use of pamidronate disodium to reduce cholecalciferol-induced toxicosis in dogs.

Rumbeiha WK, Fitzgerald SD, Kruger JM, Braselton WE, Nachreiner R, Kaneene JB, Frese KK.

Am J Vet Res. 2000 Jan;61(1):9-13.

PMID:
10630770

Supplemental Content

Loading ...
Support Center